NEWTOWN, Pa.--(BUSINESS WIRE)--Dec. 15, 2005--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today announced that it had entered into a definitive agreement to acquire all the shares of SansRosa Pharmaceutical Development Inc. (“SansRosa”). SansRosa is the assignee of various patent applications covering innovative methods for the treatment of redness associated with rosacea and other skin disorders.
